S. aureus is an important Gram-positive pathogen that colonizes the skin and mucosa of human hosts. Its ability to form biofilms is considered an important aspect of its pathogenesis1. Bacterial biofilms are a community of bacteria embedded in a self-produced matrix, which is composed of extracellular polymeric substances, including polysaccharide, DNA, and protein. This matrix plays a significant role in the persistence of bacterial infections, contributing to a high degree of resistance to the human immune system and current anti-microbial therapies2. Antibiotics are still the major treatment for biofilm infections, although the effects of antibiotics on biofilms are limited. It has been shown previously that cells in biofilms are 10 - 1,000 times more resistant to antibiotics compared to their planktonic counterparts3. Thus, alternative strategies are needed to conquer this issue.
PDT, an alternative treatment for bacterial infections, uses the light of an appropriate wavelength to activate photosensitizers. This leads to the production of reactive oxygen species (ROS), which are lethal to target cells by disrupting the cell wall, inactivating enzymes, and damaging DNA4. This multi-target characteristic makes it difficult for bacteria to develop resistance to the PDT treatment.
The antimicrobial effect of PDT on bacterial and fungal biofilms, with multiple photosensitizers, such as toluidine blue, malachite green, methylene blue, chlorine e6, and porphyrins, has been studied in previous reports5,6,7,8,9,10,11,12,13. 5-ALA, a prodrug of the actual photosensitizer, PpIX, is characterized by its small molecular weight and rapid clearance12,14. These advantages give ALA-PDT major potential as a therapeutic application. Although the effect of ALA-PDT on planktonic bacteria has been studied by many groups12, the antimicrobial effect of ALA-PDT on bacterial biofilms has not yet been elucidated. Meanwhile, it is difficult to compare the results between previous studies. One of the reasons is that the different protocols are used by diverse groups. Thus, this protocol describes an in vitro model of an ALA-PDT system based on our previous work15. The effect of this model was confirmed by CFU calculation and viability staining with CLSM.